From symptoms to biomarkers: A change of paradigm

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 11, 2014, Pages 1513-1515

  Plebani, Mario ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; BIOLOGICAL MARKER; IMMUNOGLOBULIN LIGHT CHAIN; MONOCLONAL ANTIBODY; SERUM AMYLOID A; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); TROPONIN;

AMYLOIDOSIS; CHRONIC INFLAMMATION; EDITORIAL; FOLLOW UP; HEART AMYLOIDOSIS; HUMAN; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PROGNOSIS; BLOOD; KIDNEY FAILURE, CHRONIC; METABOLISM; PATHOLOGY;

AMYLOIDOSIS; BIOLOGICAL MARKERS; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; KIDNEY FAILURE, CHRONIC; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; SERUM AMYLOID A PROTEIN; TROPONIN;

EID: 84908101881     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-0910     Document Type: Editorial

References (26)

1. Lavatelli F, Albertini R, Di Fonzo A, Palladini G, Merlini G. Biochemical markers in early diagnosis and management of systemic amyloidoses. Clin Chem Lab Med 2014;52:1517-31
2. Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood 2013;121:5124-30
3. Lachmann H, Goodman H, Gilbertson J, Gallimore J, Sabin C, Gillmore J, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:2361-71
4. Palladini G, Russo P, Bosoni T, Verga L, Sarais G, Lavatelli F, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 2009;55:499-504
5. Merlini G. Serum-free light chain analysis: works in progress. Clin Chem Lab Med 2009;47:1021-2
6. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012;30:4541-9
7. Mollee P, Tate J, Pretorius CJ. Evaluation of the N latex free light chain assay in the diagnosis and monitoring of AL amyloidosis. Clin Chem Lab Med 2013;51:2303-10
8. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012;30:989-95
9. Zweegman S, Palumbo A, Bringhen S, Sonneveld P. Age and aging in blood disorders: multiple myeloma. Haematologica 2014;99:1133-7
10. Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006;107:3854-8
11. Diomede L, Rognoni P, Lavatelli F, Romeo M, Del Favero E, Cantù L, et al. A caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis. Blood 2014;123:3543-52
12. Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013;121:3420-7
13. Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood [Epub ahead of print 2014 Aug 12]
14. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107:2440-5
15. Wechalekar AD, Gillmore JD, Wassef N, Lachmann HJ, Whelan C, Hawkins PN. Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of cardiac amyloidosis. Haematologica 2011;96:1079-80
16. Palladini G, Merlini G. Systemic amyloidoses: what an internist should know. Eur J Intern Med 2013;24:729-39
17. Zander J, Bruegel M, Kleinhempel A, Becker S, Petros S, Kortz L, et al. Effect of biobanking conditions on short-term stability of biomarkers in human serum and plasma. Clin Chem Lab Med 2014;52:629-39
18. Plebani M. Harmonization in laboratory medicine: the complete picture. Clin Chem Lab Med 2013;51:741-51
19. Weykamp C, Wielders JP, Helander A, Anton RF, Bianchi V, Jeppsson JO, et al.; IFCC Working Group on Standardization of Carbohydrate-Deficient Transferrin (WG-CDT). Toward standardization of carbohydrate-deficient transferrin (CDT) measurements: III. Performance of native serum and serum spiked with disialotransferrin proves that harmonization of CDT assays is possible. Clin Chem Lab Med 2013;51:991-6
20. Stöckl D, Van Uytfanghe K, Van Aelst S, Thienpont LM. A statistical basis for harmonization of thyroid stimulating hormone immunoassays using a robust factor analysis model. Clin Chem Lab Med 2014;52:965-72
21. Diamandis EP. A repository for "rare" tumor markers? Clin Chem Lab Med 2014;52:795-7
22. Plebani M, Melichar B. Quo vadis, biomarkers? Clin Chem Lab Med 2014;52:761-4
23. Basso D, Zambon CF, Plebani M. Inflammatory bowel diseases: from pathogenesis to laboratory testing. Clin Chem Lab Med 2014;52:471-81
24. Clerico A, Emdin M, Passino C. Cardiac biomarkers and risk assessment in patients undergoing major non-cardiac surgery: time to revise the guidelines? Clin Chem Lab Med 2014;52:959-63
25. Holzscheiter L, Beck C, Rutz S, Manuilova E, Domke I, Guder WG, et al. NGAL, L-FABP, and KIM-1 in comparison to established markers of renal dysfunction. Clin Chem Lab Med 2014;52:537-46
26. Álvarez-Fernández I, Prieto B, Rodríguez V, Ruano Y, Escudero AI, Álvarez FV. New biomarkers in diagnosis of early onset preeclampsia and imminent delivery prognosis. Clin Chem Lab Med 2014;52:1159-68.